Robotic assisted laparoscopic radical prostatectomy following transurethral resection of the prostate: perioperative, oncologic and functional outcomes

Chi-Feng Hung1,2, Cheng-Kuang Yang1, Yen-Chuan Ou1

1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
2Institute of Medicine, Chung Sang Medical University, Taichung, Taiwan

Purpose: The aim of this study was to assess surgical, oncologic and functional results after robotic-assisted laparoscopic radical prostatectomy (RALP) with and without previous transurethral resection of the prostate (TURP).

Methods: Between December 2005 and January 2010, 200 patients underwent RALP, of whom 16 (8%) had received previous TURP and 184 (92%) had not. Perioperative and postoperative data were compared between those with previous TURP (group 1) and those without previous TURP (group 2). All patients included in the study had at least 1-year follow-up.

Results: Preoperative clinical parameters were comparable between both groups. Group 1 patients were found to have significantly more need for bladder neck reconstruction (93.75 % vs. 15.21%, \( P < 0.001 \)), more rectal injury (18.75% vs. 0%, \( P < 0.001 \)), higher incidence of major complications (18.8% vs. 1.1%, \( P < 0.001 \)), and smaller specimen volume (31.63 mL vs. 45.49 mL, \( P < 0.001 \)) than group 2. The 12-month continence rate was 93.8 % in group 1 and 97.8% in group 2 (\( P = 0.344 \)). A nerve-sparing technique was significantly less successfully performed in group 1 patients than in group 2 (33.3% vs. 92.0 %, \( P = 0.001 \)).

Conclusions: Performing RALP for prostate cancer in patients who have had previous TURP is a technically demanding procedure and may be potentially associated with a higher perioperative major complication rate in short-term follow-up. Neurovascular bundle preservation is technically more challenging.

Keywords: Prostatic neoplasm, Prostatectomy, Robotics, Transurethral resection of prostate

INTRODUCTION

Incidental cancer of the prostate is found in 3%–16% of specimens from transurethral resection of the prostate (TURP) [1,2]. The results of open radical retropubic prostatectomy (RRP) or laparoscopic radical prostatectomy (LRP) for prostate cancer after previous TURP have been evaluated [3-11]. The reports are conflicting as to whether or not previous TURP worsens the prognosis after radical prostate surgery as a result of fibrous scarring and altering of tissue layers associated with difficult surgical procedures.

Since 2000, use of the da Vinci robotic system (Intuitive Surgical, Sunnyvale, CA, USA) has allowed the worldwide spread of RALP. The advantages of surgical robotics include three-dimensional visualization, seven degrees of freedom with instrument movement and absence of the fulcrum effect of conventional laparoscopy. However, limited data are available regarding robotic-assisted laparoscopic radical prostatectomy (RALP) after previous TURP [12-14]. In our previous study [15], we found that learning curve to decrease
major complications of RALP is significantly decreased after 150 cases. Nevertheless, RALP in patients with previous TURP tended to be more technically difficult and potentially associated with more perioperative complications. Hence, the aim of the present study was to examine whether previous TURP affects the oncologic safety, functional efficacy and complication rates of RALP.

MATERIALS AND METHODS

1. Patients and procedure
From December 2005 to January 2010, 200 consecutive patients with prostate cancer underwent RALP by a single surgeon (Y.C.O.) at our institution. RALP was performed after a minimum of 6 weeks after biopsy and 12 weeks after TURP. Among 200 RALPs performed, 16 patients (8%) had received previous TURP (group 1) and 184 patients (92%) had not. Recorded preoperative clinical characteristics included age, body mass index (BMI), American Society of Anesthesiologists anesthetic/surgical risks class (ASA), prostate-specific antigen (PSA) levels, PSA density, biopsy percentage, biopsy Gleason score and clinical stage (using the 2002 American Joint Committee on Cancer stage).

Transperitoneal RALP was performed as previously described [15-17]. Dissection of the bilateral pelvic lymph nodes (BPLND) was usually performed and only excluded in low-risk patients with a low likelihood (<3%) of lymph node positivity. Neurovascular bundle (NVB) sparing procedures using the Vattikuti Institute Prostatectomy technique [18] were performed depending on preoperative tumour status and each patient's choice. For low risk patients, bilateral NVB preservation was tried. For intermediate risk patients, unilateral NVB preservation was tried. And no NVB preservation will be attempted for high risk patients. Urethrovésical anastomosis was made utilizing two 18-cm 3-0 Monocryl continuous stitches. An 18-French silicon Foley catheter with a 10-mL balloon was placed. The urinary bladder was then filled with 200 mL normal saline to check for watertight anastomosis. Intraoperative and perioperative parameters were recorded for each surgery including performance of BPLND, type of NVB preservation (i.e., none, unilateral, bilateral), vesicourethral anastomosis time, surgeon's console time, estimated blood loss, transfusion rate and complications up to 180 days postoperatively. Console time was defined as the time interval while the surgeon was sitting at the surgical console using the daVinci system during the entire operation. Specimens were fixed, Indian ink-coated and serially perpendicular sectioned at 4-mm intervals. Oncologic results were recorded, including specimen volume, tumour volume, tumour percentage, Gleason score, positive surgical margin (PSM) rate, and nodal status. Perioperative complications over the 180-day postoperative period were evaluated and graded from grade 0 to grade V according to the Clavien-Dindo classification system [19]. Grade I to grade II were considered as minor complications, while grade III to grade V were classified as major complications.

Continence was defined as having no pad use. Potency was defined as achieving sufficient erection to intercourse with or without phosphodiesterase 5 inhibitor. Postoperative potency and continence data for up to 12 months were assessed and recorded. PSA or biochemical failure was regarded as two serial serum PSA results >0.2 ng/mL [20].

The preoperative, intraoperative, and postoperative data were collected, and the results were retrospectively compared between the patients with a history of resection (group 1) and those without previous TURP (group 2).

2. Statistical analysis
A retrospective cross-sectional evaluation of surgical, oncologic and functional results was made to compare groups 1 and 2. The SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Statistical analysis was carried out using the independent sample t-test & chi-square test. In all tests, $P<0.05$ was considered to indicate statistical significance.

RESULTS

As shown in Table 1, a total of 200 patient charts were reviewed, identifying 16 patients with previous TURP (group 1) and 184 without previous TURP (group 2). In group 1, there were three patients with benign pathology in the previous TURP specimens but prostate cancer was discovered during subsequent follow-up. The other 13 patients had prostate cancer incidentally identified in TURP chips. No significant differences were found between the two groups in age, BMI, ASA risk class, clinical stage, mean preoperative PSA level, free PSA, PSA density or Gleason grade from the biopsies. However, the biopsy percentage was higher in group 1 than in group 2 (33.4% vs. 21.6%, $P=0.003$).

Table 2 reveals the intraoperative data and complications. The need for bladder neck reconstruction was significantly greater in group 1 than in group 2 (93.75% vs. 15.21%, $P<0.001$). Rectal injury was higher in group 1 compared to group 2 (18.75% vs. 0%, $P<0.001$). More major complications occurred in group 1 than in group 2 (18.8% vs. 1.1%, $P<0.001$).
Table 1. Preoperative characteristics, preoperative variables during robotic-assisted laparoscopic prostatectomy in the two groups

| Variable                        | TURP                     | P-value |
|---------------------------------|--------------------------|---------|
|                                | Group 1 (Yes, n = 16)   | Group 2 (No, n = 184) |       |
| Age (yr)                        | 67.5 ± 7.4               | 64.8 ± 6.9 | 0.134  |
| Body mass index (kg/m²)         | 25.2 ± 3.5               | 24.5 ± 2.8 | 0.400  |
| ASA physical status classification system | 0.112                   |         |       |
| 1                               | 0 (0)                    | 40 (21.7) |         |
| 2                               | 14 (87.5)                | 128 (69.6)|         |
| 3                               | 2 (12.5)                 | 16 (8.7)  |         |
| PSA (ng/mL)                     | 26.44 ± 29.59            | 17.85 ± 20.27 | 0.271 |
| Free PSA (ng/mL)                | 3.51 ± 4.71              | 2.02 ± 2.20 | 0.080  |
| PSA density                     | 0.67 ± 0.54              | 0.52 ± 0.57 | 0.333  |
| Biopsy percentage               | 33.4 ± 26.0              | 21.6 ± 20.5 | 0.032  |
| Gleason score                   | 6.63 ± 1.02              | 6.59 ± 1.08 | 0.892  |
| Clinical stage                  |                          |          | 0.451  |
| T1                              | 8 (50.0)                 | 71 (38.6) |         |
| T2                              | 8 (50.0)                 | 101 (54.9) |         |
| T3                              | 0 (0)                    | 12 (6.5)  |         |

Values are presented as mean ± standard deviation or number (%).

Table 2. Patient perioperative data and complications using the Clavien classification system

| Variable                          | TURP                     | P-value |
|-----------------------------------|--------------------------|---------|
|                                   | Group 1 (Yes, n = 16)   | Group 2 (No, n = 184) |       |
| Vesicourethral anastomosis (min)  | 32.6 ± 19.9              | 30.3 ± 10.2 | 0.432  |
| Need for reconstruction of bladder neck | 15 (93.75)            | 28 (15.21) | <0.001 |
| Console time (hr)                 | 3.16 ± 1.74              | 2.95 ± 0.78 | 0.367  |
| Blood loss (mL)                   | 145.0 ± 161.4            | 183.2 ± 18.06 | 0.416  |
| Transfusion                       | 0 (0)                    | 7 (3.8)   | 1.000  |
| BPLND                             | 14 (87.5)                | 153 (83.2) | 1.000  |
| Complications                     |                          |          |       |
| Clavien grade I                   | 4 (25.0)                 | 20 (10.9) | 0.108  |
| Clavien grade II                  | 1 (25.0)                 | 5 (25.0)  | 0.004  |
| Clavien grade III                 | 0 (0)                    | 13 (65.0) |         |
| Clavien grade IV                  | 1 (25.0)                 | 2 (10.0)  |         |
| Clavien grade IV                  | 2 (50.0)                 | 0 (0)     |         |
| Minor (Clavien grade I–II)        | 1 (6.3)                  | 18 (9.8)  | <0.001 |
| Minor (Clavien grade III–V)       | 3 (18.8)                 | 2 (1.1)   |         |
| No complication                   | 12 (75.0)                | 164 (89.1)|         |
| Rectal injury                     | 3 (18.75)                | 0 (0)     | <0.001 |
| Anastomosis stricture             | 0 (0)                    | 2 (1.08)  | 1.000  |

Values are presented as mean ± standard deviation or number (%).

Table 3. Patient postoperative and oncologic results

| Variable                          | TURP                     | P-value |
|-----------------------------------|--------------------------|---------|
|                                   | Group 1 (Yes, n = 16)   | Group 2 (No, n = 184) |       |
| Foley catheter (day)              | 9.31 ± 2.82              | 9.00 ± 2.57 | 0.644  |
| Postoperative stay (day)          | 4.19 ± 2.01              | 3.77 ± 2.26 | 0.477  |
| Pathology stage                   |                          |          |       |
| pT2                               | 4 (25.0)                 | 74 (40.2) | 0.128  |
| pT3                               | 10 (62.5)                | 104 (56.5)|         |
| pT4                               | 2 (12.5)                 | 6 (3.3)   |         |
| Surgical margin positive          | 7 (43.8)                 | 74 (40.2) | 0.992  |
| pT2                               | 1 (25.0)                 | 4 (5.4)   | 0.610  |
| pT3                               | 4 (40.0)                 | 64 (61.5) | 0.199  |
| pT4                               | 2 (100)                  | 6 (100)   |         |
| Specimen volume (mL)              | 31.63 ± 8.82             | 45.49 ± 20.99 | <0.001 |
| Tumor volume                      | 7.43 ± 6.88              | 11.05 ± 11.73 | 0.226 |
| Tumor percentage                  | 22.81 ± 21.21            | 25.86 ± 24.47 | 0.631 |
| Pathology Gleason score           |                          |          |       |
| 2–4                               | 16 (100)                 | 151 (82.1)|         |
| 5–7                               | 0 (0)                    | 31 (16.8) |         |
| Node positive                     | 1 (6.3)                  | 12 (6.52) | 1.000  |
| PSA failure                       | 3 (18.8)                 | 21 (11.4) | 0.416  |

Values are presented as mean ± standard deviation or number (%).

P < 0.001. Console time, vesicourethral anastomosis time and surgical complication rate were slightly increased in group 1, although no statistically significant difference existed.

Outcome analysis is shown in Table 3. There was mild increase in the length of hospital stay and duration of bladder catheterization in group 1, but differences were not statistically significant. Mean prostate specimen volume was significantly greater in group 2 than in group 1 (31.63 mL vs. 45.49 mL, P < 0.001).

The oncological outcomes are also reported in Table 3. Pathological stages were distributed similarly between the two groups. The combined, overall PSM rate for all patients regardless of pathologic stage was 43.8% and 40.2% in groups 1 and 2, respectively (P = 0.992). The pathological Gleason score and node positive rate were similar in the two groups.

During the first year after RALP, the PSA level was measured every 3 months in all patients; at 1 year after RALP three of 16 patients (18.8%) after TURP and RALP, and 21 of 184 (11.4%) after RALP only (P = 0.416) had a PSA recurrence.

NVB preservation and functional results are presented in Table 4. The continence rate was slightly decreased in group 1 than in group 2 at 1 week, 1 month, 3 months, 6 months, and 12 months after RALP, although no statistically significant difference was observed. A nerve-sparing procedure
was attempted in 37.5% of patients in group 1 and 47.8% in group 2, separately ($P = 0.594$). Moreover, NVB preservation was successfully performed in only 33.3% of group 1 patients, compared with 92.0% of group 2 patients ($P = 0.001$). The NVB seemed to be less able to be free from the prostatic capsule after previous TURP. In group 1, two patients had bilateral NVB preservation and had potency after 12 months. In group 2, 65 patients had potency after 12 months, including 17 who had unilateral NVB preservation and 48 who had bilateral NVB preservation.

**DISCUSSION**

After the introduction of PSA measurement and the increasing use of transrectal ultrasound-guided biopsies, the frequency of detected prostate cancer at prostate chips during TURP has decreased [21]. The results from different series of open, laparoscopic and robot-assisted prostatectomies after

---

### Table 4. Functional results after RALP and neurovascular bundle preservation

| Variable                        | TURP Group 1 (Yes, n = 16) | TURP Group 2 (No, n = 184) | $P$-value |
|---------------------------------|-----------------------------|-----------------------------|-----------|
| Continence within               |                             |                             |           |
| 1 Week                          | 4 (25.0)                    | 72 (39.1)                   | 0.396     |
| 1 Months                        | 9 (56.3)                    | 114 (62.0)                  | 0.855     |
| 3 Months                        | 14 (87.5)                   | 172 (93.5)                  | 0.310     |
| 6 Months                        | 15 (93.8)                   | 179 (97.3)                  | 0.398     |
| 12 Months                       | 15 (93.8)                   | 180 (97.8)                  | 0.344     |
| Attempt to NVB preservation     | 6 (37.5)                    | 88 (47.8)                   | 0.594     |
| Successful NVB preservation     | 2 (33.3)                    | 81 (92.0)                   | 0.001     |
| Incidence NVB preservation      | 2 (12.5)                    | 81 (44.0)                   | 0.029     |
| Potency at 12 months            | 2 (100)                     | 65 (80.3)                   | 1.000     |
| Bilateral NVB                   | 2 (100)                     | 48 (73.8)                   | 1.000     |
| Unilateral NVB                  | 0 (0)                       | 17 (26.2)                   |           |

Values are presented as number (%).

RALP, robotic-assisted radical prostatectomy; TURP, transurethral resection of prostate; NVB, neurovascular bundle.

### Table 5. Surgical, oncologic and functional results after open radical retropubic prostatectomy (RRP), laparoscopic radical prostatectomy (LRP), extraperitoneal laparoscopic radical prostatectomy (ELRP) and robotic-assisted radical prostatectomy (RALP) with and without previous transurethral resection of the prostate (TURP) in the literature

| Investigator | Technique | Perioperative outcome & complication rate | Oncological outcome | Functional outcome |
|--------------|-----------|------------------------------------------|---------------------|--------------------|
| Palisaar et al. [3] | RRP | No higher complication rate | Insignificantly higher PSM rate and PSA failure rate | Similar complete urinary control rate |
| Colombo et al. [4] | RRP | Longer operative time, increased morbidity rate | Insignificantly higher PSM rate and PSA failure rate | Less satisfactory functional results |
| Do et al. [6] | ELRP | Comparable perioperative outcome, higher complication rate | Comparable oncological outcome | Similar continence rate |
| Teber et al. [7] | LRP | Longer operative time, comparable complication rate | Comparable oncological outcome | Delayed continence time |
| Menard et al. [8] | LRP | Worse perioperative outcome, higher surgical complication rate | Comparable oncological outcome | Similar continence rate |
| Jaffe et al. [9] | LRP | Longer operative time, length of stay, higher overall complication rate | Higher PSM rate | NR |
| Eden et al. [10] | LRP | Longer catheterization time, no difference in complication rate | Similar PSM rate | Delayed continence time |
| Martin et al. [12] | RALP | Longer catheterization time, no difference in complication rate | Similar PSM rate | No difference in erection rates |
| Gupta et al. [13] | RALP | Greater blood loss and a need for bladder neck reconstruction | Higher PSM rate | Higher incontinence rate |
| Zugor et al. [14] | RALP | More need for bladder neck reconstruction, longer operative time, more minor complication rate | Comparable PSM rate | Delayed continence and potency time |

PSM, positive surgical margin; PSA, prostate-specific antigen; NR, not recorded; NVB, neurovascular bundle.
TURP in the literature are summarized on Table 5. The effects of previous TURP on open RRP are controversial. Palisaar et al. [3] used a case-controlled design to match 62 cases (with previous TURP) with an equivalent number of controls (without previous TURP). Matching parameters included patient age, BMI, prostate volume, preoperative PSA level, Gleason score, pathological stage and nerve-sparing procedure. After complete 1-year follow-up, they reported that previous TURP does not cause a higher perioperative complication rate nor a worse functional result. The overall PSM rates and one-year biochemical recurrence rates were comparable in their study.

Colombo et al. [4] examined 109 patients who had RRP for prostate cancer, all of whom had previous operation for bladder outlet obstruction. Among 88 of these 109 patients, the previous intervention was TURP. They reported that RRP could be safely undertaken with slightly increased morbidity after previous prostate surgery, but erectile function and urinary continence were compromised in contrast to patients with no previous treatment.

The effect of previous TURP on LRP is also debated. Do et al. [6] stated that 100 of 2,300 patients had endoscopic extraperitoneal radical prostatectomy after previous TURP. That procedure is technically more challenging, but perioperative, functional and short-term oncologic outcomes are promising and are directly equal to outcomes without previous TURP. However, the potency results were inferior in the patients with previous TURP.

Teber et al. [7] described outcomes of LRP in clinical T1a and T1b prostate cancer. They reported that LRP is oncologically safe. The recovery to total continence was delayed, but the potency rates remained unaffected if a nerve-sparing procedure was executed. Menard et al. [8] revealed that LRP after TURP would not hinder the oncologic results, but that it was related to poorer intraoperative and postoperative outcomes. Also, NVB preservation was technically more difficult and negatively affected postoperative erectile function.

Jaffe et al. [9] described poorer surgical outcomes in men undergoing LRP after TURP, inclusive of operative time, length of stay, PSM rate, and overall complication rate but without mentioning the functional results. However, Eden et al. [10] reported the functional results after LRP in patients with previous bladder outlet surgery, and did not find any difference even in the nerve-sparing procedures.

As for RALP, few results are reported comparing RALP outcomes in patients with and without previous prostate treatment. Martin et al. [12] evaluated 24 patients receiving RALP who had a history of previous treatment to the prostate compared to 486 men without previous treatment and concluded that a history of previous treatment of the prostate does not seem to compromise the perioperative outcomes of RALP. Gupta et al. [13] compared outcomes of RALP in 26 patients with TURP to 132 cases of RALP without TURP and discovered a longer operating time, higher operative difficulty and hampered oncological or continence outcomes. Zugor et al. [14] used a match-paired analysis to compare 80 cases with previous TURP with an equivalent number of controlled patients and reported that technically more demanding, a prolonged operative time and time interval before continence and potency returns in patients with a previous TURP. But it can be safely performed without compromising functional results. Our results found significant increase in the need of bladder neck reconstruction, more rectal injury, major complications and difficulty in the NVB preservation procedure in the patients receiving RALP with previous TURP.

In the literature describing open RRP or LRP after TURP, most authors described the procedure as being more difficult [4-8]. Perforation of the prostatic capsule during TURP with extravasation of blood and irrigation fluid can result in peri-prostatic fibrosis and distortion of the surgical planes [4,5]. We observed increased need for bladder neck reconstruction, more vesicourethral anastomosis time, console time, catheter duration, hospital stay, major complication rate and less chance to successful NVB preservation in the patients who had previously undergone TURP, probably suggesting the suspicion that prior TURP does add to the complexity of RALP, although these did not reach statistical significance except for the need for bladder neck reconstruction, rectal injury, major complication rate and successful rate of NVB preservation.

In our experience, the three cases with rectal injuries occurred in cases #81, 125, 129, with none observed in the first 50 patients [22]. The operative difficulties were mainly encountered during identification of the anterior bladder neck, resection of the posterior part of the bladder neck and when starting dissection of the posterior plane of the prostate. Technical difficulties were also encountered during dissection of the apex and identification of the urethral stump; however, it is less likely to objectively quantify these parameters. To avoid rectal injury in RALP, dissection of the prostatic apex should be made carefully and sharply with cold scissors instead of an electrical energy source to prevent thermal damage. Also, the rectum should be hold posteriorly by the assistant during dissection the recto-urethral muscle from the posterolateral angle. In addition, it is mandatory to adequately incise the posterior layer of Denovillier’s fascia to avoid false entry into the perirectal fat after completing dissection of both seminal
vesicles. Previous TURP results in a wide bladder neck, which can sometimes be very close to the ureteral orifices, suggesting that these structures could be easily injured during dissection of the posterior bladder neck. In an attempt to visualize the ureteral orifices by insertion of double-J stents bilaterally, ureteral injury can be avoided [6]. In the first two cases of group 1, double-J stents were inserted to clearly identify the ureteral orifices; however, in the following cases, we were more confident to identify the ureteral orifices under direct vision from robotic laparoscope and did not insert double-J stents. A wider bladder neck also increased the time of bladder neck sparing and bladder neck reconstruction (tennis racket method) during vesicourethral anastomosis.

Do et al. [6] and Menard et al. [8] performed LRP at least 3 months after the TURP procedure since, by that time, the peri-prostatic inflammation caused by the TURP had probably subsided and conditions in the operative field would have been more favourable. Elder et al. [23] recommended that radical perineal prostatectomy should be performed during the first month after TURP or after a time interval of 4 months. In our series, RALP was routinely carried out after a minimum of 6 weeks post biopsy and 12 weeks post TURP.

A statistically significant difference was observed between group 1 and group 2 in this study in the weight of the prostatic specimens (31.63 mL vs. 45.49 mL, respectively, \( P < 0.001 \)). This result seems to be in contrast to the data from other reports [8,9]. Jaffe et al. [9] suggested that patients with a history of TURP have larger prostates that, after resection, are then similar to the size of prostates in men who did not undergo TURP. In our series, this result may be due to much more prostate tissue removed when TURP.

Oncological outcome is the primary end-point for patients with prostate cancer receiving radical prostatectomy. The technical difficulties did not seem to have much influence in the short-term oncologic outcomes after RALP for the patients with previous TURP, as shown by the overall PSM rate and the 1-year biochemical failure rate. In the current series, the PSM rate for pT2, pT3, and pT4 patients was 25%, 40%, and 100%, respectively, and the overall PSM rate was 43.8% in patients with previous TURP. Other series of LRP and RALP in patients with previous prostate treatment reported overall PSM rates of 6.25%–26.1% [6,8-10,12-14]. PSM frequency is influenced by surgical technique (procedure, ability and experience), tumour features (size, aggressiveness, extension) and pathological analysis [24]. PSM rates in our study seem to be higher compared to other series. This may be explained as a result of our surgical population having higher PSA results and a higher incidence of high-risk patients than in other series.

In terms of functional outcomes, our data revealed no statistical significance in continence and potency results among two groups. Although statistically significant differences were not observed in preoperative PSA levels and preoperative Gleason scores between the groups with and without previous TURP, the isolation and preservation of the NVBs was technically feasible in only 33.3% of patients after TURP, compared to 92.0% in the patients without previous TURP. The nerve sparing technique appeared to us to be more difficult in patients with previous TURP, and many investigators concur [4,6,8]. This difficulty results from greater tissue reaction and periprostatic fibrosis caused by fluid extravasation during TURP. However, we demonstrated that potency could be achieved if a nerve-sparing procedure was possible after previous TURP. The aetiology of erectile dysfunction after radical prostatectomy is multifactorial, and neurogenic factors and thermal injury seem to play a crucial role [8,25]. Therefore, a history of TURP should also be viewed as a risk factor for erectile dysfunction after RALP.

Patient age, preoperative International Prostate Symptom Score (IPSS) and anastomotic stricture development were considered to be independent risk factors for incontinence after radical prostatectomy [8,26]. Nevertheless, Kessler et al. [27] showed a significant effect of nerve-sparing surgery on urinary continence. We observed differences between the TURP and non-TURP groups with regard to the nerve sparing procedures, but the continence rates were somewhat lower in patients with previous TURP at 1 week, 1 month, 3 months, 6 months and 12 months after RALP, even though no significant differences were found.

The present study has several limitations and study results should be carefully interpreted. First and most important, this is a small series and there were significantly fewer patients in group 1 than in group 2. Second, this was a retrospective study and the time interval between TURP and RALP was not consistent, which could be an important variable, substantially contributing to the degree of periprostatic inflammation and scarring over time. Third, the technical difficulties, (e.g., identification of anterior bladder neck, resection of posterior part of bladder neck, and dissection of posterior plane of prostate) are hard to objectively quantify; therefore, is definitely a limitation of this study. Fourth, we know that the postoperative functional results should have employed validated questionnaires and that the lack of preoperative continence and erectile function status determination might introduce bias into the analysis. Fifth, a multi-institutional study with more long-term and large-scale data, including rates of PSA failure, continence and potency, are needed to examine the
efficacy of RALP in the patients with previous TURP.

In conclusion, previous TURP represents a technical challenge for performing RALP, and the perioperative results, the incidence of major complications and short-term functional outcomes of RALP may be inferior to those of patients without TURP. NVB preservation is more technically demanding. We suggest that these potential risks should be clearly explained to patients with history of TURP who are candidates for RALP and the procedure should be handled by an experienced robotic surgeon.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol 2006;50:969-79.
2. Merrill RM, Wiggins CL. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 2002;7:213-9.
3. Palisaar JR, Wenske S, Sommerer F, Hinkel A, Noldus J. Open radical retropubic prostatectomy gives favourable surgical and functional outcomes after transurethral resection of the prostate. BJU Int 2009;104:611-5.
4. Colombo R, Naspro R, Salonia A, Montorsi F, Raber M, Suardi N, et al. Radical prostatectomy after previous prostate surgery: clinical and functional outcomes. J Urol 2006;176(6 Pt 1):2459-63.
5. Ramon J, Rossignol G, Leandri P, Gautier JR. Morbidity of radical retropubic prostatectomy following previous prostate resection. J Surg Oncol 1994;55:14-9.
6. Do M, Haefner T, Liatsikos E, Kallidonis P, Hicks J, Dietel A, et al. Endoscopic extraperitoneal radical prostatectomy after previous transurethral resection of prostate: oncologic and functional outcomes of 100 cases. Urology 2010;77:216-21.
7. Katz R, Borkowski T, Hoznek A, Salomon L, Gettman MT, Abbou CC. Laparoscopic radical prostatectomy in patients following transurethral resection of the prostate. Urol Int 2006;77:216-21.
8. Martin AD, Desai PJ, Nunez RN, Martin GL, Andrews PE, Ferrigni RG, et al. Does a history of previous surgery or radiation to the prostate affect outcomes of robot-assisted radical prostatectomy? BJU Int 2009;103:1696-8.
9. Jaffe J, Stakhovsky O, Cathelineau X, Barret E, Vallancien G, Rozet E. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate. J Urol 2007;178:483-7.
10. Eden CG, Richards AJ, Ooi J, Moon DA, Laczko I. Previous bladder outlet surgery does not affect medium-term outcomes after laparoscopic radical prostatectomy. BJU Int 2007;99:399-402.
11. Eden CG, Richards AJ, Ooi J, Moon DA, Laczko I. Previous bladder outlet surgery does not affect medium-term outcomes after laparoscopic radical prostatectomy. BJU Int 2007;99:399-402.
12. Menon M, Hemal AK; VIP Team. Vattikuti Institute prostatectomy. BJU Int 2011;108:420-5.
13. Oppenheimer AR, Chen JT, Yang CR, Cheng CL, Patel VR, et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int 2011;108:420-5.
14. Zugor V, Labanaris AP, Porres D, Witt JH. Surgical, oncologic, and short-term functional outcomes in patients undergoing robot-assisted prostatectomy after previous transurethral resection of the prostate. J Endourol 2012;26:515-9.
15. Ou YC, Yang CR, Wang J, Yang CK, Cheng CL, Patel VR, et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int 2011;108:420-5.
22. Hung CF, Yang CK, Cheng CL, Ou YC. Bowel complication during robotic-assisted laparoscopic radical prostatectomy. Anticancer Res 2011;31:3497-501.

23. Elder JS, Gibbons RP, Correa RJ Jr, Brannen GE. Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J Urol 1984;132:55-7.

24. Koch MO. Positive margins in urological oncology. J Urol 2007; 178:2249.

25. Ahlering TE, Rodriguez E, Skarecky DW. Overcoming obstacles: nerve-sparing issues in radical prostatectomy. J Endourol 2008;22:745-50.

26. Lee DJ, Cheetham P, Badani KK. Predictors of early urinary continence after robotic prostatectomy. Can J Urol 2010;17:5200-5.

27. Kessler TM, Burkhard FC, Studer UE. Nerve-sparing open radical retropubic prostatectomy. Eur Urol 2007;51:90-7.